- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Intralesional acyclovir effective option for treatment of cutaneous warts, study finds
Egypt: Acyclovir, an antiviral drug, is a potential therapeutic option to eradicate the human papillomavirus (HPV), a recent study has revealed.
The study, published in the Journal of Cutaneous Medicine and Surgery, found that intralesional acyclovir is a well-tolerated and effective treatment modality for cutaneous warts.
Elaborating on the need for this study, the researchers write that the treatment of warts is challenging, and developing an antiviral drug that can eradicate HPV is difficult. Acyclovir, an antiviral drug with proven efficacy in DNA viruses, could be a potential therapeutic option considering the viral origins of warts.
Ayman Elsayed, Department of Dermatology, Venereology and Andrology, Faculty of Medicine, Zagazig University, Egypt, and colleagues, therefore, aimed to evaluate the efficacy and safety of intralesional acyclovir in the treatment of cutaneous warts.
The study included thirty-one patients with cutaneous warts. They were allocated into 2 groups -- Group A included 19 patients who had intralesional acyclovir, 70 mg/ml was injected into warts, while group B included 12 patients who received intralesional saline as control. The treatment was repeated at 2-week intervals until complete clearance or for a maximum of 5 sessions.
The results of the study were found to be:
• Complete clearance of warts was observed in 52.6%, partial response in 36.8%, and no response in 10.5% of the patients in the acyclovir group.
• Partial response was reported in 16.7%, and no response in 83.3% of the patients in the control group.
• A high statistically significant difference was found between the treatment and control groups.
• Adverse effects included pain during injection in 89.5%, blistering in 52.6% and erythema in5.3% of the patients. No recurrence was observed during the follow-up period.
Elsayed and the team concluded that "Intralesional acyclovir can be an effective and well-tolerated treatment modality for cutaneous warts." Antiviral breakdown of HPV can be controlled to a greater extent.
Reference:
1.Elsayed A, Nassar A, Marei A, Hoseiny HAM, Alakad R. Intralesional Acyclovir: A Potential Therapeutic Option for Cutaneous Warts. Journal of Cutaneous Medicine and Surgery. August 2021. doi:10.1177/12034754211037998
Medical Dialogues consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751